Allogeneic CAR T data keep CRISPR Therapeutics competitive
Readout does not shed light on concerns of unintended edits
With efficacy holding steady and no new serious safety issues, the latest data for CTX110 puts the allogeneic CAR T cell therapy from CRISPR Therapeutics in a position to compete with autologous products, but it’s not enough to provide relief for investors on edge since a competing program sparked safety concerns last week.
CRISPR Therapeutics AG (NASDAQ:CRSP) was off 8% to $94 in after-hours trading on Tuesday after announcing that the CD19-targeting allogeneic CAR T cell therapy led to an overall response rate of 58% in the intent-to-treat population of 24 large B cell lymphoma patients, a complete response of 38% and a favorable safety profile...
BCIQ Target Profiles